Human Reproduction, Vol. 15, No. 7, 1490-1498,
July 2000
© 2000 European Society of Human Reproduction and Embryology
Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial
A multicentre, open-label, randomized study of the gonadotrophin-releasing hormone (GnRH) antagonist ganirelix (Orgalutran®/AntagonTM) was performed in women undergoing ovarian stimulation with recombinant FSH (rFSH: Puregon®). The study was designed as a non-inferiority study using a long protocol of buserelin (intranasal) and rFSH as a reference treatment. A total of 730 subjects was randomized in a treatment ratio of 2:1 (ganirelix:buserelin) using an interactive voice response system which stratified for age, type of infertility and planned fertilization procedure [IVF or intracytoplasmic sperm injection (ICSI)]. The median duration of GnRH analogue treatment was 5 days in the ganirelix group and 26 days in the buserelin group, whereas the median total rFSH dose was 1500 IU and 1800 IU respectively. In addition, in the ganirelix group the mean duration of stimulation was 1 day shorter. During ganirelix treatment the incidence of LH rises (LH 
10 IU/l) was 2.8% versus 1.3% during rFSH stimulation in the buserelin group. On the day of triggering ovulation by human chorionic gonadotrophin (HCG), the mean number of follicles 11 mm diameter was 10.7 and 11.8, and the median serum oestradiol concentrations were 1190 pg/ml and 1700 pg/ml in the ganirelix and buserelin groups respectively. The mean number of oocytes per retrieval was 9.1 and 10.4 respectively, whereas the mean number of good quality embryos was 3.3 and 3.5 respectively. The fertilization rate was equal in both groups (62.1%), and the same mean number of embryos (2.2) was replaced. The mean implantation rates were 15.7% and 21.8%, and the ongoing pregnancy rates per attempt were 20.3% and 25.7% in the ganirelix and buserelin groups respectively. Evaluation of all safety data indicated that the ganirelix regimen was safe and well tolerated. The overall incidence of ovarian hyperstimulation syndrome was 2.4% in the ganirelix group and 5.9% in the reference group. The results of this study support a safe, short and convenient treatment regimen of ganirelix, resulting in a good clinical outcome for patients undergoing ovarian stimulation for IVF or ICSI.
Key words: buserelin/ganirelix/GnRH agonist/GnRH antagonist/ICSI/IVF/ovarian stimulation/recombinant FSH
1 To whom correspondence should be addressed at: NV Organon, P.O. Box 20, 5340 BH Oss, The Netherlands. E-mail: b.mannaerts{at}organon.oss.akzonobel.nl
* T.Åbyholm (Kvinneklinikken, Rikshospitalet, Oslo, Norway); D.Barlow (John Radcliffe Hospital, Oxford, UK); P.Devroey (Academic Hospital, Free University Brussels, Brussels, Belgium); K.Diedrich (Medizinische Universität zu Lübeck, Lübeck, Germany); J.Donnez (Clinique Universitair Brussels, Belgium); V.von Düring (Regionsykehuset I Trondheim, Trondheim, Norway); B.Fauser (Dijkzigt Academic Hospital, Rotterdam, The Netherlands); L.Hamberger (Sahlgrenska Sjukhuset, Götenborg, Sweden); T.Hillensjö (Fertilitets Centrum, Carlanderska Sjukhuset, Götenborg, Sweden); J.N.Hugues (Hôpital Jean Verdier, Bondy, France); C.Jansen (Diaconessenhuis, Voorburg, The Netherlands); J.Kahn (The Fertility Clinic Ciconia, Copenhagen, Denmark); J.Blaabjerg (Herlev Hospital, Herlev, Denmark); F.Olivennes (Hôpital Antoine Béclère, Clamart, France); A.Pellicer (Instituto Valenciano de Infertilidad, Valencia, Spain); S.Pavlou (Mitera Fertility and IVF Unit, Athens, Greece); T.Rabe (Universitätsklinikum, Heidelberg, Germany); A.Rutherford (Leeds General Infirmary, Leeds, UK); B.Tarlatzis (Infertility IVF Centre `Geniki Cliniki', Thessaloniki, Greece); L.Westergaard (Odense Sygehus, Odense, Denmark); B.Mannaerts and G.Borm (Research and Development, NV Organon, Oss, The Netherlands)
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  The Corifollitropin Alfa Dose-finding Study Group A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation Hum. Reprod., August 6, 2008; (2008) den288v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.A. Huirne, R. Homburg, and C.B. Lambalk Are GnRH antagonists comparable to agonists for use in IVF? Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Asimakopoulos, F. Koster, R. Felberbaum, S. Al-Hasani, K. Diedrich, and N. Nikolettos Cytokine and hormonal profile in blood serum and follicular fluids during ovarian stimulation with the multidose antagonist or the long agonist protocol Hum. Reprod., December 1, 2006; 21(12): 3091 - 3095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.M. Kolibianakis, J. Collins, B.C. Tarlatzis, P. Devroey, K. Diedrich, and G. Griesinger Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis Hum. Reprod. Update, November 1, 2006; 12(6): 651 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Gustofson, J. H. Segars, and F. W. Larsen Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome Hum. Reprod., November 1, 2006; 21(11): 2830 - 2837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Messinis Ovarian feedback, mechanism of action and possible clinical implications Hum. Reprod. Update, September 1, 2006; 12(5): 557 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.A. Huirne, J.N. Hugues, C. Pirard, F. Fischl, J.C. Sage, J.L. Pouly, A. Obruca, D.M. Braat, A.C.D. van Loenen, and C.B. Lambalk Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study Hum. Reprod., June 1, 2006; 21(6): 1408 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Kolibianakis, E. G. Papanikolaou, M. Camus, H. Tournaye, A. C. Van Steirteghem, and P. Devroey Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists Hum. Reprod., April 1, 2006; 21(4): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.B. Lambalk, A. Leader, F. Olivennes, M.R. Fluker, A. N. Andersen, J. Ingerslev, Y. Khalaf, C. Avril, J. Belaisch-Allart, R. Roulier, et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial Hum. Reprod., March 1, 2006; 21(3): 632 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Kolibianakis, E. G. Papanikolaou, M. Camus, H. Tournaye, A. C. Van Steirteghem, and P. Devroey Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial Hum. Reprod., February 1, 2006; 21(2): 352 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rombauts, D. Healy, R. J. Norman, and on behalf of the Orgalutran Scheduling Study Group A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients Hum. Reprod., January 1, 2006; 21(1): 95 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Abdalla and M.Y. Thum Repeated testing of basal FSH levels has no predictive value for IVF outcome in women with elevated basal FSH Hum. Reprod., January 1, 2006; 21(1): 171 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.E. Messinis, D. Loutradis, E. Domali, C.P. Kotsovassilis, L. Papastergiopoulou, A. Kallitsaris, P. Drakakis, K. Dafopoulos, and S. Milingos Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment Hum. Reprod., November 1, 2005; 20(11): 3192 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ragni, W. Vegetti, A. Riccaboni, B. Engl, C. Brigante, and P.G. Crosignani Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome Hum. Reprod., September 1, 2005; 20(9): 2421 - 2425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lainas, J. Zorzovilis, G. Petsas, G. Stavropoulou, H. Cazlaris, V. Daskalaki, G. Lainas, and E. Alexopoulou In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF Hum. Reprod., September 1, 2005; 20(9): 2426 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ragni, A. Allegra, P. Anserini, F. Causio, A.P. Ferraretti, E. Greco, R. Palermo, E. Somigliana, and on behalf of the Societa Italiana della Riproduzio The 2004 Italian legislation regulating assisted reproduction technology: a multicentre survey on the results of IVF cycles Hum. Reprod., August 1, 2005; 20(8): 2224 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Prapas, Y. Prapas, Y. Panagiotidis, S. Prapa, P. Vanderzwalmen, R. Schoysman, and G. Makedos GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study Hum. Reprod., June 1, 2005; 20(6): 1516 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Humaidan, H. Ejdrup Bredkjaer, L. Bungum, M. Bungum, M.L. Grondahl, L. Westergaard, and C. Yding Andersen GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study Hum. Reprod., May 1, 2005; 20(5): 1213 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A.F. Huirne, A. C.D. van Loenen, R. Schats, J. McDonnell, P. G.A. Hompes, J. Schoemaker, R. Homburg, and C. B. Lambalk Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy Hum. Reprod., February 1, 2005; 20(2): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.H. Mochtar and on behalf of The Dutch Ganirelix Study Group The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI Hum. Reprod., August 1, 2004; 19(8): 1713 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, A. Rutherford, R. Fleming, C. C.K. Tay, G. Trew, W. Ledger, and D. Cahill A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction Hum. Reprod., January 1, 2004; 19(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Kolibianakis, C. Albano, M. Camus, H. Tournaye, A. C. Van Steirteghem, and P. Devroey Initiation of Gonadotropin-Releasing Hormone Antagonist on Day 1 as Compared to Day 6 of Stimulation: Effect on Hormonal Levels and Follicular Development in in Vitro Fertilization Cycles J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5632 - 5637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fanchin, L. Salomon, A. Castelo-Branco, F. Olivennes, N. Frydman, and R. Frydman Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists Hum. Reprod., December 1, 2003; 18(12): 2698 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. P. Hohmann, N. S. Macklon, and B. C. J. M. Fauser A Randomized Comparison of Two Ovarian Stimulation Protocols with Gonadotropin-Releasing Hormone (GnRH) Antagonist Cotreatment for in Vitro Fertilization Commencing Recombinant Follicle-Stimulating Hormone on Cycle Day 2 or 5 with the Standard Long GnRH Agonist Protocol J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 166 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.B. Engel, M. Ludwig, R. Felberbaum, C. Albano, P. Devroey, and K. Diedrich Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'? Hum. Reprod., August 1, 2002; 17(8): 2022 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Boerrigter, J. J. de Bie, B. M.J.L. Mannaerts, B. P. van Leeuwen, and D. P.J. Passier-Timmermans Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix Hum. Reprod., August 1, 2002; 17(8): 2027 - 2034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Herbst, B. D. Anawalt, J. K. Amory, and W. J. Bremner Acyline: The First Study in Humans of a Potent, New Gonadotropin-Releasing Hormone Antagonist J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3215 - 3220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Al-Inany GnRH agonist versus antagonist therapy Hum. Reprod., May 1, 2002; 17(5): 1413 - 1413. [Full Text] [PDF]
|
|
|
|
|
|
H. Al-Inany and M. Aboulghar GnRH antagonist in assisted reproduction: a Cochrane review Hum. Reprod., April 1, 2002; 17(4): 874 - 885. [Abstract] [Full Text]
|
|
|
|
|
|
M. Bonduelle, I. Liebaers, V. Deketelaere, M.-P. Derde, M. Camus, P. Devroey, and A. Van Steirteghem Neonatal data on a cohort of 2889 infants born after ICSI (1991-1999) and of 2995 infants born after IVF (1983-1999) Hum. Reprod., March 1, 2002; 17(3): 671 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Fauser, D. de Jong, F. Olivennes, H. Wramsby, C. Tay, J. Itskovitz-Eldor, and H. G. van Hooren Endocrine Profiles after Triggering of Final Oocyte Maturation with GnRH Agonist after Cotreatment with the GnRH Antagonist Ganirelix during Ovarian Hyperstimulation for in Vitro Fertilization J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 709 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Garcia-Velasco, V. Isaza, C. Vidal, A. Landazabal, J. Remohi, C. Simon, and A. Pellicer Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix) Hum. Reprod., December 1, 2001; 16(12): 2533 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Al-Innay Subgroup analyses in Orgalutran trials Hum. Reprod., December 1, 2001; 16(12): 2726 - 2726. [Full Text] [PDF]
|
|
|
|
|
|
B. Mannaerts, E. van Hooren, and P. Boerrigter Subgroup analyses in Orgalutran trials Hum. Reprod., December 1, 2001; 16(12): 2726 - 2726. [Full Text] [PDF]
|
|
|
|
|
|
G. Ragni, W. Vegetti, E. Baroni, M. Colombo, M. Arnoldi, G. Lombroso, and P. G. Crosignani Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist Hum. Reprod., November 1, 2001; 16(11): 2258 - 2262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. GORDON Gonadotropin-Releasing Hormone Antagonists: Implications for Oocyte Quality and Uterine Receptivity Ann. N.Y. Acad. Sci., September 1, 2001; 943(1): 49 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wikland, C. Bergh, K. Borg, T. Hillensjo, C.M. Howles, A. Knutsson, L. Nilsson, and M. Wood A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI Hum. Reprod., August 1, 2001; 16(8): 1676 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filicori and G. E. Cognigni Roles and Novel Regimens of Luteinizing Hormone and Follicle-Stimulating Hormone in Ovulation Induction J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1437 - 1441. [Abstract] [Full Text]
|
|
|
|
|
|
O. Ortmann, J.M. Weiss, and K. Diedrich Embryo implantation and GnRH antagonists: Ovarian actions of GnRH antagonists Hum. Reprod., April 1, 2001; 16(4): 608 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. European Middle East Orgalutran Study Group* Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation Hum. Reprod., April 1, 2001; 16(4): 644 - 651. [Abstract] [Full Text] [PDF]
|
|